Oral Rivaroxaban Reduces Risk of Recurrent VTE with No Increase in Bleeding

Oral rivaroxaban’s efficacy at reducing the risk of recurrent venous thromboembolism (VTE) was confirmed in two trials presented at the annual meeting of the American Society of Hematology. The agent was studied for treatment of deep-vein thrombosis (DVT) as well as for continued therapy after initial anticoagulation treatment for DVT or pulmonary embolism.
 
For the DVT study, the EINSTEIN Investigators randomized 3449 patients with symptomatic DVT to rivaroxaban or enoxaparin plus either warfarin or acenocoumarol for 3, 6, or 12 months. Rivaroxaban was taken twice daily (15 mg) for 3 weeks, with a maintenance dose (20 mg daily) for the remainder of the study period. Enoxaparin was taken at a weight-adjusted dose until the international normalized ratio was 2 or greater for 2 days and after a minimum of 5 days of treatment. Patients in both groups received a vitamin K antagonist throughout the study period.
 
Rivaroxaban significantly reduced DVT risk over enoxaparin (P <.001). Major bleeding or clinically relevant nonmajor bleeding, the primary safety outcome, occurred in 8.1% of patients in both groups.
 
For the continuation study, the investigators randomized 1200 patients with symptomatic DVT or pulmonary embolism who had been treated for 6 to 12 months with a vitamin K antagonist to rivaroxaban (20 mg daily) or placebo for an additional 6 to 12 months.
 
Treatment with rivaroxaban also significantly reduced the risk of recurrent VTE over placebo (P <.001). Nonfatal major bleeding, the safety end point, occurred in four patients in the rivaroxaban group compared with zero in the placebo group (P = .11).
 
These finding were also published online in the New England Journal of Medicine (December 3, 2010).
Related Items
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Graft-versus-Host Disease: Breakthroughs on the Horizon
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Basket Clinical Trials: A New Era in Cancer Treatment
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Chemotherapy Treatment Considerations in Special Patient Populations
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Nivolumab/Ipilimumab Combination Extends Survival for Patients with Melanoma
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Melanoma, AACR News, Conference Correspondent
Pursuit of Biomarkers for CDK4/CDK6 Response Fails
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in AACR News, Conference Correspondent
Abemaciclib Moves Forward in Metastatic Breast Cancer
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in AACR News, Conference Correspondent
Updated NCCN Guidelines for Neuroendocrine Tumors and Carcinoid Syndrome Features New Therapies
Wayne Kuznar
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, NCCN
Last modified: September 9, 2019